Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics
This is a randomized, single intravenous dose, parallel study to compare the PK characteristics, safety, tolerability, and immunogenicity of HLX05 vs. Erbitux® (US-, EU-, and CN-sourced) in healthy adult male Chinese subjects.
Cancer|mCRC
DRUG: HLX05|DRUG: EU-Erbitux®|DRUG: US-Erbitux®|DRUG: CN-Erbitux®
Area under the serum concentration-time curve from time 0 to infinity (AUC0-inf), up to 29 days
Cmax, Maximum serum concentration, up to 29 days|Tmax, Time to reach maximum serum concentration, up to 29 days|CL, Total clearance, up to 29 days|λz, Apparent terminal elimination rate constant, up to 29 days
This is a randomized, single intravenous dose, parallel study to compare the PK characteristics, safety, tolerability, and immunogenicity of HLX05 vs. Erbitux® (US-, EU-, and CN-sourced) in healthy adult male Chinese subjects.